← CA Feed
BUSINESS

Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis

· sa transcript insights editor

Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis

AI Briefing

  • Nektar Therapeutics sets $400M-$460M year-end 2026 cash target
  • REZPEG Phase IIb wins
  • REZPEG enters Phase III in atopic dermatitis
Advertisement
Read Original Article

Related Dispatches